Elsevier

Thrombosis Research

Volume 129, Supplement 1, April 2012, Pages S132-S136
Thrombosis Research

Microparticles in tumor progression

https://doi.org/10.1016/S0049-3848(12)70033-6Get rights and content

Abstract

Microparticles (MP) are shed from the surface of activated or apoptotic blood cells and their levels in plasma reflect a balance between cell stimulation, proliferation, and death. MP production occurs through vesiculation of cell membranes, and involves cytoskeletal changes and a shift in the normal phospholipid asymmetry. The expression on the majority of MP of the anionic phosphatidylserine (PS) is responsible for the capacity of MP to support blood coagulation activation. In some cases, PS expression is also associated, in the same MP, with the presence of active Tissue Factor, the main activator of blood coagulation. Elevation in plasma levels of MP have been described in numerous clinical conditions, most of which also associated with an increased thrombotic risk. Particularly, MP have been found to be increased in both solid and hematological malignancies, including myeloproliferative neoplasms. A role of MP in tumor progression has been suggested by both in vitro and in vivo studies. Evidence exists that MP of platelet origin are the main players in this process, being rich in pro-angiogenic factors. The utility of measuring MP as a diagnostic and prognostic marker is currently a subject of intense investigation. The possibility to inhibit MP production by pharmacological interventions represents a future challenge.

References (62)

  • A Falanga et al.

    Procoagulant mechanisms in tumour cells

    Best Pract Res Clin Haematol

    (2009)
  • HK Kim et al.

    Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor

    Eur J Cancer

    (2003)
  • I Del Conde et al.

    Microvesicle-associated tissue factor and Trousseau's syndrome

    J Thromb Haemost

    (2007)
  • RE Tilley et al.

    Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients

    Thromb Res

    (2008)
  • JL Yu et al.

    Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis

    Blood

    (2005)
  • N Magnus et al.

    Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells

    Blood

    (2010)
  • M Davila et al.

    Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation

    J Thromb Haemost

    (2008)
  • DA Manly et al.

    Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism

    Thromb Res

    (2010)
  • S Kanazawa et al.

    Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer

    Lung Cancer

    (2003)
  • ME Tesselaar et al.

    Microparticle-associated tissue factor activity: a link between cancer and thrombosis?

    J Thromb Haemost

    (2007)
  • ME Tesselaar et al.

    Microparticle-associated tissue factor activity in cancer patients with and without thrombosis

    J Thromb Haemost

    (2009)
  • JI Zwicker

    Predictive value of tissue factor bearing microparticles in cancer associated thrombosis

    Thromb Res

    (2010)
  • AA Khorana et al.

    Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer

    J Thromb Haemost

    (2008)
  • MC Van Aalderen et al.

    Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy

    J Thromb Haemost

    (2011)
  • P Prandoni et al.

    Cancer and venous thromboembolism

    Lancet Oncol

    (2005)
  • M Prokopi et al.

    Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures

    Blood

    (2009)
  • W Ruf et al.

    Tissue factor in cancer progression and angiogenesis

    Thromb Res

    (2010)
  • V Sustar et al.

    Suppression of membrane microvesiculation – a possible anticoagulant and anti-tumor progression effect of heparin

    Blood Cells Mol Dis

    (2009)
  • MJ VanWijk et al.

    Microparticles in cardiovascular diseases

    Cardiovasc Res

    (2003)
  • JI Zwicker et al.

    Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy

    Clin Cancer Res

    (2009)
  • W Jy et al.

    Measuring circulating cell-derived microparticles

    J Thromb Haemost

    (2004)
  • Cited by (54)

    • Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes

      2022, Thrombosis Research
      Citation Excerpt :

      TF expressed by breast cancer cells can efficiently activate TG in vitro [25,26], but can also be responsible for the increased VEGF expression [27] and microparticle (MPs) shedding from the same breast cancer cells [28]. MPs are important actors in angiogenesis and hypercoagulability, being plentiful in proangiogenic and prothrombotic factors [29], and in cancer, MPs can be of both tumor and vascular cell (i.e., platelets, leukocytes, erythrocytes, endothelial cells) origins [30,31]. Increased MPs procoagulant activity are found in breast cancer patients after adjuvant and neoadjuvant chemotherapy [32].

    • Hemostatic biomarkers in cancer progression

      2018, Thrombosis Research
      Citation Excerpt :

      Tumor TF expression was an independent prognostic indicator for OS in breast cancer [65] and for DFS in osteosarcoma [66]. Under pathological conditions, TF can be detected at increased concentration in plasma where it circulates alone or associated to cellular derived microparticles (MP) expressing also the procoagulant phosphatidylserine (PS) [67, 68]. TF-containing MP is the main source of TF activity released from human cancer cells [69].

    • Mechanisms and risk factors of thrombosis in cancer

      2017, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      These small membrane vesicles carry high concentrations of procoagulant phosphatidylserine and TF (Falanga et al., 2012). The pathogenetic role of MPs in cancer-associated thrombosis is demonstrated by the development of a DIC-like syndrome in mice after intravenous injection of highly TF-positive MPs of tumor origin (Falanga et al., 2012). Elevated levels of circulating MPs have been described in cancer patients, with both solid and hematologic malignancies and play a role in the establishment of the hypercoagulable state (Falanga and Marchetti, 2009; Tilley et al., 2008; Del Conde et al., 2007; Kim et al., 2003).

    View all citing articles on Scopus
    View full text